The patient was diagnosed with bronchogenic adenocarcinoma and received carboplatin, pemetrexed, and pembrolizumab, which alleviated the esophageal stricture and cancerous lymphangiopathy. However, the adenocarcinoma progressed, and she subsequently received several rounds of chemotherapy. One year after ...
Carboplatin/pembrolizumab/pemetrexed. Reactions Weekly 1779, 59 (2019). https://doi.org/10.1007/s40278-019-71323-1 Download citation Published16 November 2019 Issue DateNovember 2019 DOIhttps://doi.org/10.1007/s40278-019-71323-1 Access this article Log in via an institution Subscribe and save...
1文献来源Langer CJ,Gadgeel SM,Borghaei H,et al.Carboplatin and Pemetrexed with or without Pembrolizumab for advanced,non-squamous non-small-cell lung cance... 范云,张嘉涛 - 《循证医学》 被引量: 1发表: 2017年 Comparative efficacy and safety of second-line treatments for advanced non-small...
PURPOSE: This multicenter, phase II clinical study was conducted to evaluate the activity of the combination of pemetrexed and carboplatin in patients with... Ceresoli,L G. - 《Journal of Clinical Oncology》 被引量: 392发表: 2006年 Carboplatin and pemetrexed with or without pembrolizumab for adva...
In combination with pembrolizumab, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC)...
(≥ 50% expression) tumors that would not be amenable to genetic mutation-based targeted therapies.6 However, as reported in the KEYNOTE-001 and -010 tri- als, 23% to 28% of NSCLC tumors exhibit ≥ 50% PD-L1 expression.7,8 In addition, pembrolizumab plus pemetrexed (Eli Lilly and ...
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Lancet Oncol (2016)View more references Cited by (360) Gemcitabine and cisplatin plus durvalumab with or without tremelim...
973MO - KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC Ann Oncol, 33 (suppl 7) (2022), pp. S448-S554 Google Scholar 18 C. Zhou, Z. Wang, J. Yang A protocol pre-...
Pembrolizumab monotherapy or immune checkpoint inhibitor with platinum and pemetrexed combination chemotherapy are the standard therapies for patients with nonsquamous non-small-cell lung cancer (NSCLC) with programmed cell death ligand-1 (PD-L1) tumor proportion score (TPS) ≥ 50%. However, there ar...
nab paclitaxel+Carboplatin+Paclitaxel+Pembrolizumab+Pemetrexed sslrlnjrgl(mnsygsjrwz) = gyqvqddqyl kpaghesafn (fhhkjygppk, rshnndpqol - lqygsqnutp) View more - 21 Oct 2024 Login to view more data Translational Medicine Boost your research with our translational medicine data. ...